BioCardia, Inc. (NASDAQ:BCDA) Short Interest Up 927.5% in March

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,010,000 shares, a growth of 927.5% from the February 29th total of 98,300 shares. Based on an average trading volume of 378,600 shares, the short-interest ratio is presently 2.7 days. Currently, 6.2% of the company’s stock are sold short.

Insider Buying and Selling at BioCardia

In other news, CEO Peter Altman acquired 108,108 shares of BioCardia stock in a transaction on Tuesday, February 13th. The stock was purchased at an average price of $0.46 per share, with a total value of $49,729.68. Following the completion of the purchase, the chief executive officer now owns 555,447 shares of the company’s stock, valued at approximately $255,505.62. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, major shareholder Phillip Md Et Al Frost sold 129,802 shares of BioCardia stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $0.43, for a total transaction of $55,814.86. Following the transaction, the insider now owns 1,896,025 shares of the company’s stock, valued at $815,290.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Peter Altman bought 108,108 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were bought at an average cost of $0.46 per share, for a total transaction of $49,729.68. Following the transaction, the chief executive officer now owns 555,447 shares of the company’s stock, valued at $255,505.62. The disclosure for this purchase can be found here. Insiders own 23.90% of the company’s stock.

Institutional Trading of BioCardia

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in BioCardia during the fourth quarter worth $27,000. CM Management LLC raised its stake in shares of BioCardia by 74.9% in the third quarter. CM Management LLC now owns 600,000 shares of the company’s stock valued at $258,000 after buying an additional 257,000 shares during the period. BlackRock Inc. bought a new stake in shares of BioCardia in the second quarter valued at $88,000. Geode Capital Management LLC raised its stake in shares of BioCardia by 50.3% in the second quarter. Geode Capital Management LLC now owns 145,155 shares of the company’s stock valued at $388,000 after buying an additional 48,561 shares during the period. Finally, Millennium Management LLC bought a new stake in shares of BioCardia in the second quarter valued at $42,000. 20.57% of the stock is currently owned by institutional investors.

BioCardia Stock Performance

Shares of BioCardia stock opened at $0.42 on Thursday. The business’s fifty day simple moving average is $0.44 and its 200 day simple moving average is $0.50. The firm has a market capitalization of $10.86 million, a P/E ratio of -0.68 and a beta of 1.50. BioCardia has a 12 month low of $0.36 and a 12 month high of $2.92.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.